Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
To hold US shares via HL you simply complete an additional form and as a non-US resident it can save tax. Even if 4D do delist from AIM it shouldn't cause an issue and if it does you need to move platforrn.
The vaccine isn't going to be available in the UK any time soon either -
"So far, the UK does not stand to benefit from the vaccine. Moderna has agreed deals to provide the US with 100 million doses, with an option to buy 400 million more. Japan, Canada, Switzerland, Qatar and Israel have also signed agreements, and the European Commission has a “potential purchase agreement” for 8 to 160 million doses. The UK chose not to participate in the EU scheme, with Matt Han**** arguing in July that the government could source vaccine faster on its own."
https://www.theguardian.com/world/2020/nov/16/moderna-covid-vaccine-candidate-almost-95-effective-trials-show
This really is starting to get painful. I've been adding and averaging down since the Covid dip but for me it's not possible to look at NCYT and not think that I backed the wrong horse. I have no doubt we will win the scientific argument but delivering BAMS and LFT with exquisite S&S is kind of irrelevant if the market is saturated with competitor's tests. Yes the testing market will be around for a long time to come but the longer this goes on, the lower the potential reward is becoming. It amazes me how competitors can deliver numerous new products and AS can't deliver anything in the same time.
Completely agree WG.
The 4D covid trial has been delayed due to there being less people hospitalised by covid and not being able to get enough patients for the next trial. DP said they were pushing their case with Han****. It would give a short term boost to the SP no doubt as we would attract investment from those chasing Covid stocks but like you infer, it's a side show. The real value here is in the Oncology and IBS work, which makes a mockery of the SP drop when the Pfizer efficacy vaccine results were announced.
On the bright side it provides a great opportunity to top up at these prices. I can't believe the SP fell below the NASDAQ merger price.
Brilliant article scrambler and IMO a must read for any 4D investor. Thanks for sharing.
Scientific research into microbiomes is still in its infancy but there now appears to be widespread scientific acceptance that microbiomes influence many aspects of health. 4D is at the cutting edge of this research with an unrivalled platform and range of patents.
Some competitors are experimenting with multiple strains however I much prefer 4D's single strain approach as it simplifies the process and route to MHRA / FDA approval. There may be potential to combine multiple approved treatments in future.
The IP alone makes 4D a fantastic investment but the fact they are pushing ahead with clinical trials makes them an obvious take over target for large pharma companies looking to enter this market in future as other wise they may have to licence 4D's IP.
Exciting times. Bring on NASDAQ
https://threadreaderapp.com/thread/1325918245879242754.html
Well worth a read as the outcome will drastically impact the need for testing
and sell when others are being greedy.
09/11/2020 Bought B782645212 110.00 2,807 3,099.65
09/11/2020 Bought B781746802 102.60 4,666 4,799.27
Luckily I could still login to HL to top up!
We knew 6 vaccines were in phase 3 trials before today and the signs on efficacy were good. We also knew that mass testing would still be required for a long time to come despite vaccines being ready. The Boris press conference / Biden statement confirmed this earlier. When the TT is complete and government orders follow, this SP will rocket IMO.
Yes there are risks around the TT and most of us thought the LFT would be ready by now but there is still massive upside from this SP so the R/R is very attractive, again IMO.
On a separate note, the 'I told you so' gloating from some posters when others are under water is very poor form and premature.
10% is undeniably steep in an environment of zero interest rates however, the terms must be more attractive than the existing borrowing otherwise Fortune would not have chosen to restructure the debt.
Orion are also prepared to convert at a significant premium to the current share price, which is a huge show of confidence IMO.
I'm, perhaps wrongly, struggling to see how these developments can be seen as negative?
You don't request to present results in 3 seperate SITC presentations unless the data is extremely good! This could be ground breaking for oncology and put DDDD on the radar of significant investors and partners.
So having done extensive research Merck have committed £millions to developing 4D Pharma's LBPs . The SPAC company 4D are doing the merger with have invested millions having done extensive research. The Directors have committed £millions of their own money, obviously knowing the potential of 4D.
The NASDAQ listing will gain 4D attention from investors who more favourably value companies like 4D. 4D are also presenting results at high profile events in Q4 to gain even more investor intention. This time next year Rodney....
I like the proposed NASDAQ handle too - LBPS (live biotherapeutics!)
A merger at an 18% premium to current share price with a NASDAQ listing and there are some questioning whether this is a positive RNS! Have a look at the market cap of Seres, who are NASDAQ listed with IMO less going for it than 4D. My point yesterday about this BB being a joke stands.
This BB has literally become a waste of space over the past couple of weeks. I check in to read comments and 90% are people speculating about the short term price fluctuations that may or may not happen. Who cares? Generally just ramping and de-ramping BS with very little foundation.
This company specialise in live biotherapeutics (LBP), which is a relatively new field but has the potential to lead to huge medical advancements so there is now significantly more focus on LBP. There have been studies and trials to date that have demonstrated efficacy with an incredible safety profile. Merck, a multi-billion pound pharma company, thinks that there is great potential in LBP and have multiple partnerships with 4D Pharma.
The success and long term share price of this company will be determined by the outcome of the clinical trials so who cares about what the share price will do by close, next week or whether some gap gets filled? Let the traders make their 10% by calling the gap correctly and then p***ing off.
There are no guarantees of anything but if Merck with their endless resources have studied all the data and think it’s worth investing millions to find out then who am I to question? If they’re wrong then we will lose a lot of money but if they’re right this company will be worth many multiples of the current SP. I will be holding on tightly to my shares until that point.
If you're not planning on selling any shares in the near future then why obsess with the short term price fluctuations?
If the price drops to 80p next week I won't be selling any of my shares. If the SP rises to £1.30 next week I won't be selling any shares so it's an irrelevant paper loss / gain either way.
If you think the company will be worth significantly more than the current SP over the period which you intend to hold then why would you sell any shares? If you think it's going to be worth less over the course of your investment term in this share then why are you holding? Just ignore the noise and nonsense of others.
Capitalising on all those PI's who **** the bed and gave away their shares having not understood the RNS
Blue, you have literally no idea what you're talking about or are trying to deramp.
Two separate analysts from leading pharma companies said congratulations on the data before asking their questions at the end of the presentation. Which opinion has more credibility, theirs or yours?
This is going to phase III and is just one trial, alongside the cancer and covid trials.
What are these people talking about.... there is no approved treatment for IBS M and this trial just delivered great results for patients with IBS M.
The results for IBS C and IBS D were comparable to existing approved treatments but with fewer side effects.
That's the problem with pharma stocks - a load of people invested with literally no idea what they're invested in.
It's always a good sign when Mizo starts to de-ramp, the share price normally retraces to a new recent high!
After his last attempt the share price reached 5.4p a short time later and that high will be a thing of the past once the mining license is agreed, funding secured and MOUs are converted to binding agreements.
You know full well this is a different management team to the one that disappointed shareholders so badly previously and includes Matt Bull, who has 800k of his own money invested, has a fantastic CV and so far has delivered on this project too. Yes, a few deadlines have been missed along the way but we all know this project is heading in the right direction.
The question to ask is, what value does making contradictory statements without any substance give Mizo? If like he claims, he needs an 8p share price to break even then why would he deramp? Surely he would want to the share price to appreciate to regain some of his losses. Or is it that he missed the boat and is now trying to deramp to get in at a lower price? hmmm, I wonder